PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
Código da empresaPMCB
Nome da EmpresaPharmaCyte Biotech Inc
Data de listagemSep 11, 2003
CEOMr. Joshua N. (Josh) Silverman
Número de funcionários2
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 11
Endereço3960 Howard Hughes Parkway, Suite 500
CidadeLAS VEGAS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal89169
Telefone19175952850
Sitehttps://pharmacyte.com/
Código da empresaPMCB
Data de listagemSep 11, 2003
CEOMr. Joshua N. (Josh) Silverman
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados